Assessing Bruker (BRKR) Valuation After Recent Share Price Rebound And Mixed Fair Value Signals

Simply Wall St.04-07

AdvertisementBruker stock performance snapshot Bruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625660197?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-07 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625660197","market":"us","top_or_hot":-1,"title":"Assessing Bruker (BRKR) Valuation After Recent Share Price Rebound And Mixed Fair Value Signals","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementBruker stock performance snapshot Bruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/assessing-bruker-brkr-valuation-after-recent-share-price-reb\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Bruker (BRKR) Valuation After Recent Share Price Rebound And Mixed Fair Value Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Bruker (BRKR) Valuation After Recent Share Price Rebound And Mixed Fair Value Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 04:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/assessing-bruker-brkr-valuation-after-recent-share-price-reb><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementBruker stock performance snapshot Bruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/assessing-bruker-brkr-valuation-after-recent-share-price-reb\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BRKR","symbol_name":"布鲁克","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/assessing-bruker-brkr-valuation-after-recent-share-price-reb","article_id":"2625660197","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/assessing-bruker-brkr-valuation-after-recent-share-price-reb","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625660197","pubTimestamp":1775506442,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bruker stock performance snapshot\nBruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over the past week.\nLooking a bit further back, Bruker is roughly flat over the past month and has a 30.2% decline over the past 3 months. Year to date, the stock shows a 23.6% decline, with a 4.5% decline over the past year.\nOver longer horizons, Bruker’s 3 year total return reflects a 53% decline, while the 5...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BRKR":"布鲁克","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4121":"生命科学工具和服务","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC"},"translate_title":"在近期股价反弹和混合公允价值信号后评估布鲁克(BRKR)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRKR":1.5,"DCF":1},"content_text":"AdvertisementBruker stock performance snapshot Bruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over the past week. Looking a bit further back, Bruker is roughly flat over the past month and has a 30.2% decline over the past 3 months. Year to date, the stock shows a 23.6% decline, with a 4.5% decline over the past year. Over longer horizons, Bruker’s 3 year total return reflects a 53% decline, while the 5 year total return shows a 44.7% decline. These figures provide context for assessing how current fundamentals relate to past shareholder outcomes. See our latest analysis for Bruker. The recent 7 day share price return of 7.1% comes after a year in which total shareholder return declined 4.5%, and the 3 year total shareholder return declined 53%, so recent momentum follows a longer period of weaker outcomes. If Bruker’s moves have you reassessing where you put fresh capital, this can be a good moment to broaden your watchlist and uncover 20 top founder-led companies With the share price under pressure over the past year but recent returns turning positive, and with analyst targets sitting above the current US$36.76 level, the key question is whether there is a buying opportunity here or if the market is already pricing in future growth. Most Popular Narrative: 23.2% Undervalued Bruker’s most followed narrative pegs fair value at about $47.86 per share, versus the last close of $36.76, and builds a case around future earnings power under an 8.65% discount rate.  The expected stabilization and eventual recovery of research and biopharma funding in both the US and China, along with global settlements on tariffs, could trigger a rebound in demand for Bruker's advanced life science and drug discovery instruments, supporting renewed top-line revenue growth post-2025.  Read the complete narrative. Want to see what sits behind that optimism on funding, margins and earnings? The narrative leans on a detailed path for revenue, profitability and the future profit multiple applied to those earnings. Result: Fair Value of $47.86 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside story still hinges on research funding not staying weak for too long and on Bruker delivering its planned cost savings without demand slipping further. Find out about the key risks to this Bruker narrative. Another View: Cash Flows Paint A Tighter Picture While the analyst narrative sees Bruker as about 23% undervalued at $47.86 per share, the Simply Wall St DCF model is more cautious and puts future cash flow value closer to $35.78. With the stock at $36.76, that points to a mild premium rather than a clear discount. For a closer look at how those cash flow assumptions stack up against the narrative and price target, Look into how the SWS DCF model arrives at its fair value. BRKR Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bruker for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed messages across narratives and valuation models can be a useful signal to look closer rather than sit on the fence. Take a moment to review the numbers, understand both the red flags and potential upsides, and weigh them against your own expectations with the help of the 2 key rewards and 1 important warning sign Looking for more investment ideas? If Bruker has sharpened your focus, do not stop here. Use this momentum to scan wider, compare alternatives and keep your capital working on your terms.  Target resilient balance sheets and clear fundamentals with the solid balance sheet and fundamentals stocks screener (40 results). Hunt for quality companies that trade below estimated worth using the 58 high quality undervalued stocks. Spot potential future standouts before the crowd by checking the screener containing 25 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bruker might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625660197","isCrawlerRequest":true}